Literature DB >> 12185073

A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function.

Allison P Armstrong1, Mark E Tometsko, Moira Glaccum, Claire L Sutherland, David Cosman, William C Dougall.   

Abstract

Signaling through receptor activator of nuclear factor-kappaB (RANK) is essential for the differentiation and activation of osteoclasts, the cell principally responsible for bone resorption. Animals genetically deficient in RANK or the cognate RANK ligand are profoundly osteopetrotic because of the lack of bone resorption and remodeling. RANK provokes biochemical signaling via the recruitment of intracellular tumor necrosis factor receptor-associated factors (TRAFs) after ligand binding and receptor oligomerization. To understand the RANK-mediated signal transduction mechanism in osteoclastogenesis, we have designed a system to recapitulate osteoclast differentiation and activation in vitro by transfer of the RANK cDNA into hematopoietic precursors genetically deficient in RANK. Gene transfer of RANK constructs that are selectively incapable of binding different TRAF proteins revealed that TRAF pathways downstream of RANK that affect osteoclast differentiation are functionally redundant. In contrast, the interaction of RANK with TRAF6 is absolutely required for the proper formation of cytoskeletal structures and functional resorptive activity of osteoclasts. Moreover, signaling via the interleukin-1 receptor, which also utilizes TRAF6, rescues the osteoclast activation defects observed in the absence of RANK/TRAF6 interactions. These studies are the first to define the functional domains of the RANK cytoplasmic tail that control specific differentiation and activation pathways in osteoclasts.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12185073     DOI: 10.1074/jbc.M202009200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  73 in total

1.  Molecular mechanisms of the biphasic effects of interferon-γ on osteoclastogenesis.

Authors:  Jing Cheng; Jianzhong Liu; Zhenqi Shi; Joel Jules; Duorong Xu; Shaokai Luo; Shi Wei; Xu Feng
Journal:  J Interferon Cytokine Res       Date:  2011-12-05       Impact factor: 2.607

2.  Simvastatin inhibits osteoclast differentiation by scavenging reactive oxygen species.

Authors:  Ho Jin Moon; Sung Eun Kim; Young Pil Yun; Yu Shik Hwang; Jae Beum Bang; Jae Hong Park; Il Keun Kwon
Journal:  Exp Mol Med       Date:  2011-11-30       Impact factor: 8.718

3.  Aspirin inhibits osteoclastogenesis by suppressing the activation of NF-κB and MAPKs in RANKL-induced RAW264.7 cells.

Authors:  Yan-Ping Zeng; Chao Yang; Yuan Li; Yong Fan; Hong-Jun Yang; Bin Liu; Hong-Xun Sang
Journal:  Mol Med Rep       Date:  2016-06-30       Impact factor: 2.952

Review 4.  Osteoclasts: New Insights.

Authors:  Xu Feng; Steven L Teitelbaum
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

5.  The IVVY Motif and Tumor Necrosis Factor Receptor-associated Factor (TRAF) Sites in the Cytoplasmic Domain of the Receptor Activator of Nuclear Factor κB (RANK) Cooperate to Induce Osteoclastogenesis.

Authors:  Joel Jules; Shunqing Wang; Zhenqi Shi; Jianzhong Liu; Shi Wei; Xu Feng
Journal:  J Biol Chem       Date:  2015-08-14       Impact factor: 5.157

6.  Cloning and characterization of osteoclast precursors from the RAW264.7 cell line.

Authors:  Bethany L V Cuetara; Tania N Crotti; Anthony J O'Donoghue; Kevin P McHugh
Journal:  In Vitro Cell Dev Biol Anim       Date:  2006 Jul-Aug       Impact factor: 2.416

7.  RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis.

Authors:  Jin Gohda; Toru Akiyama; Takako Koga; Hiroshi Takayanagi; Sakae Tanaka; Jun-ichiro Inoue
Journal:  EMBO J       Date:  2005-01-27       Impact factor: 11.598

Review 8.  RANKL inhibition: a promising novel strategy for breast cancer treatment.

Authors:  Eva González-Suárez
Journal:  Clin Transl Oncol       Date:  2011-04       Impact factor: 3.405

9.  RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor.

Authors:  Christopher A Nelson; Julia T Warren; Michael W-H Wang; Steven L Teitelbaum; Daved H Fremont
Journal:  Structure       Date:  2012-10-02       Impact factor: 5.006

10.  CKIP-1 regulates macrophage proliferation by inhibiting TRAF6-mediated Akt activation.

Authors:  Luo Zhang; Yiwu Wang; Fengjun Xiao; Shaoxia Wang; Guichun Xing; Yang Li; Xiushan Yin; Kefeng Lu; Rongfei Wei; Jiao Fan; Yuhan Chen; Tao Li; Ping Xie; Lin Yuan; Lei Song; Lanzhi Ma; Lujing Ding; Fuchu He; Lingqiang Zhang
Journal:  Cell Res       Date:  2014-04-29       Impact factor: 25.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.